Home > Neurology > ECTRIMS 2021 > Experimental Treatments > Elezanumab did not outperform placebo in progressive and relapsing MS

Elezanumab did not outperform placebo in progressive and relapsing MS

Presented By
Prof. Bruce Cree, University of California, CA, USA
Conference
ECTRIMS 2021
Trial
Phase 2, RADIUS-R, RADIUS-P
Elezanumab did not improve physical function or disability in patients with relapsing or progressive MS. The drug showed favourable safety and tolerability profiles and is currently investigated in other neurological conditions [1]. Elezanumab is a fully humanised, monoclonal antibody, selectively binding to repulsive guidance molecule A (RGMa). This molecule is an inhibitor of axon regeneration, neurite outgrowth, and remyelination in the CNS. Antibody neutralisation of RGMa has been linked to enhanced neuronal regeneration and increased neuroprotection in animal models [2]. RADIUS-R (NCT03737851; n=208) and RADIUS-P (NCT03737812; n=123), 2 randomised, double-blind, placebo-controlled, phase 2 trials investigated the efficacy and safety of elezanumab as add-on treatment i...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on